Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders

• US 6,214,806 B1
• Filed: 02/25/1998
• Issued: 04/10/2001
• Est. Priority Date: 02/28/1997
• Status: Expired due to Fees

• Current Assignee: Iowa University of Research Foundation
• Original Assignee: University of Iowa Research Foundation
• Inventors: Krieg, Arthur M., Schwartz, David A.
• Primary Examiner(s): Elliott, George C.
• Assistant Examiner(s): LARSON, THOMAS GEORGE
• Application Number:
  US09/030,701
• Time in Patent Office: 1,140 Days
• Field of Search: 514/44, 536/24.3, 536/24.5, 536/23.1, 536/25.6
• US Class Current: 514/44.00A
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

The present invention is based on the finding that nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide affect immune responses in a subject. These nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide can be used to treat pulmonary disorders having an immunologic component, such as a response to inhaled lipopolysaccharide. The invention provides methods of treating subjects who have or are at risk of having these pulmonary disorders, and methods of altering the immunological components of the pulmonary disorders. The invention also provides pharmaceutical compositions for treating pulmonary disorders that have an immunologic component.

Claims

1. A method of treating a subject having or at risk of having an acute decrement in air flow, comprising:

administering to a subject having or at risk of having an acute decrement in air flow, wherein the acute decrement in air flow results from endotoxin exposure, a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG.

2. The method of claim 1, wherein the nucleic acid sequence is from 8-30 bases in length.

3. The method of claim 1, wherein the subject is human.

4. The method of claim 1, wherein the acute decrement in airflow results from lipopolysaccharide (LPS) exposure.

5. The method of claim 1, wherein the nucleic acid sequence has a formula:

6. The method of claim 5, wherein N₁ and N₂ do not contain a CCGG quadmer or more than one CGG trimer;

and the nucleic acid sequence is from about 8-30 bases in length.

7. The method of claim 5, wherein said nucleic acid sequence is SEQ ID NO:

2.

8. The method of claim 1, wherein the nucleic acid sequence has a formula:

9. The method of claim 8, wherein N₁ and N₂ do not contain a CCGG quadmer or more than one CCG or CGG trimer;

and the nucleic acid sequence is from about 8-30 bases in length.

10. The method of claim 1 wherein the endotoxin exposure results from inhalation of LPS.

11. The method of claim 10 wherein the endotoxin exposure results in dust-induced airway disease.

12. The method of claim 10 wherein the endotoxin exposure results in LPS-induced asthma.

13. The method of claim 1 wherein the endotoxin exposure results in adult respiratory distress syndrome (ARDS).

14. The method of claim 1 wherein the endotoxin exposure results in endotoxemia.

15. The method of claim 1 wherein the endotoxin exposure results in systemic inflammatory response syndrome SIRS.

16. The method of claim 1 wherein the endotoxin exposure results in sepsis syndrome.

17. The method of claim 1 wherein the endotoxin exposure results in septic shock.

18. The method of claim 1 wherein the endotoxin exposure results in disseminated intravascular coagulation (DIC).

19. The method of claim 1 wherein the endotoxin exposure results in cardiac dysfunction.

20. The method of claim 1 wherein the endotoxin exposure results in organ failure, wherein the organ failure is selected from the group consisting of liver failure, brain failure, renal failure, and multi-organ failure.

21. The method of claim 1 wherein the endotoxin exposure results from a route of administration selected from the group consisting of administration of LPS-contaminated fluids and gram-negative infections.

22. The method of claim 1 wherein the subject is a subject who has been treated with chemotherapy.

23. The method of claim 1 wherein the subject is an immunocomprised subject.

24. The method of claim 1 wherein the nucleic acid sequence containing at least one unmethylated CpG is administered by a route selected from the group consisting of intravenous, parenteral, oral, implant and topical.

25. A method of inhibiting an inflammatory response in a subject having inhaled or at risk of having inhaled lipopolysaccharide (LPS), comprising:

administering to a subject having inhaled or at risk of having inhaled LPS, a therapeutically effective amount for inhibiting an inflammatory response of a nucleic acid sequence containing at least one unmethylated CpG.

26. The method of claim 25, wherein the nucleic acid sequence is from 8-30 bases in length.

27. The method of claim 25, wherein the subject is human.

28. The method of claim 25, wherein the nucleic acid sequence has a formula:

29. The method of claim 28, wherein N₁ and N₂ do not contain a CCGG quadmer or more than one CGG trimer;

and the nucleic acid sequence is from about 8-30 bases in length.

30. The method of claim 28, wherein said nucleic acid sequence is SEQ ID NO:

2.

31. The method of claim 25, wherein the nucleic acid sequence has a formula:

32. The method of claim 31, wherein N₁ and N₂ do not contain a CCGG quadmer or more than one CCG or CGG trimer;

and the nucleic acid sequence is from about 8-30 bases in length.

33. A method of modifying the level of a cytokine in a subject having inhaled or at risk of having inhaled lipopolysaccharide (LPS), comprising:

administering to a subject having inhaled or at risk of having inhaled LPS a therapeutically effective amount for modifying the level of a cytokine of a nucleic acid sequence containing at least one unmethylated CpG dinucleotide.

34. The method of claim 33, wherein the nucleic acid sequence is from 8-30 bases in length.

35. The method of claim 33, wherein the subject is human.

36. The method of claim 33, wherein said nucleic acid sequence is SEQ ID NO:

2.

37. The method of claim 33, wherein the nucleic acid sequence has a formula:

38. The method of claim 37, wherein N₁ and N₂ do not contain a CCGG quadmer or more than one CGG trimer;

and the nucleic acid sequence is from about 8-30 bases in length.

39. The method of claim 33, wherein the nucleic acid sequence has a formula:

40. The method of claim 39, wherein N₁ and N₂ do not contain a CCGG quadmer or more than one CCG or CGG trimer;

and the nucleic acid sequence is from about 8-30 bases in length.

41. The method of claim 33, wherein said modulation is a reduction in the level of said cytokine.

42. The method of claim 33, wherein said modulation is an increase in the level of said cytokine.

43. The method of claim 33, wherein said cytokine is selected from the group consisting of TNF-α

, MIP-2, IL-10, IL-12, and interferon-γ

.